| Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a … T Pillinger, RA McCutcheon, L Vano, Y Mizuno, A Arumuham, G Hindley, ... The Lancet Psychiatry 7 (1), 64-77, 2020 | 689 | 2020 |
| Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? RM Murray, D Quattrone, S Natesan, J Van Os, M Nordentoft, O Howes, ... The British Journal of Psychiatry 209 (5), 361-365, 2016 | 289 | 2016 |
| Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology SJ Kaar, S Natesan, R Mccutcheon, OD Howes Neuropharmacology 172, 107704, 2020 | 284 | 2020 |
| Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models S Natesan, GE Reckless, JN Nobrega, PJ Fletcher, S Kapur Neuropsychopharmacology 31 (9), 1854-1863, 2006 | 230 | 2006 |
| Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats EC Onwordi, EF Halff, T Whitehurst, A Mansur, MC Cotel, L Wells, ... Nature communications 11 (1), 246, 2020 | 187 | 2020 |
| Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation AC Vernon, S Natesan, M Modo, S Kapur Biological psychiatry 69 (10), 936-944, 2011 | 183 | 2011 |
| Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson’s disease F Niccolini, T Foltynie, T Reis Marques, N Muhlert, AC Tziortzi, GE Searle, ... Brain 138 (10), 3003-3015, 2015 | 117 | 2015 |
| Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation AC Vernon, S Natesan, WR Crum, JD Cooper, M Modo, SCR Williams, ... Biological psychiatry 71 (10), 855-863, 2012 | 115 | 2012 |
| Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease F Niccolini, S Haider, T Reis Marques, N Muhlert, AC Tziortzi, GE Searle, ... Brain 138 (10), 3016-3029, 2015 | 107 | 2015 |
| The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 … S Natesan, KA Svensson, GE Reckless, JN Nobrega, KBL Barlow, ... Journal of Pharmacology and Experimental Therapeutics 318 (2), 810-818, 2006 | 105 | 2006 |
| Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses MC Cotel, EM Lenartowicz, S Natesan, MM Modo, JD Cooper, ... European Neuropsychopharmacology 25 (11), 2098-2107, 2015 | 102 | 2015 |
| Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs—linking magnetic resonance imaging findings to cellular pathology AC Vernon, WR Crum, JP Lerch, W Chege, S Natesan, M Modo, ... Biological psychiatry 75 (12), 982-990, 2014 | 102 | 2014 |
| A method for tapering antipsychotic treatment that may minimize the risk of relapse MA Horowitz, S Jauhar, S Natesan, RM Murray, D Taylor Schizophrenia Bulletin 47 (4), 1116-1129, 2021 | 95 | 2021 |
| Amisulpride the ‘atypical’atypical antipsychotic—comparison to haloperidol, risperidone and clozapine S Natesan, GE Reckless, KBL Barlow, JN Nobrega, S Kapur Schizophrenia Research 105 (1-3), 224-235, 2008 | 86 | 2008 |
| Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine M Kokkinou, EE Irvine, DR Bonsall, S Natesan, LA Wells, M Smith, ... Molecular psychiatry 26 (6), 2562-2576, 2021 | 77 | 2021 |
| The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D1 agonist and D2 antagonist S Natesan, GE Reckless, KBL Barlow, J Odontiadis, JN Nobrega, ... Psychopharmacology 199, 275-289, 2008 | 70 | 2008 |
| The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study S Jauhar, M Veronese, MM Nour, M Rogdaki, P Hathway, S Natesan, ... Biological psychiatry 85 (1), 79-87, 2019 | 67 | 2019 |
| Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment D Amato, S Natesan, L Yavich, S Kapur, CP Müller International Journal of Neuropsychopharmacology 14 (10), 1327-1339, 2011 | 58 | 2011 |
| Evaluation of N-desmethylclozapine as a potential antipsychotic—preclinical studies S Natesan, GE Reckless, KBL Barlow, JN Nobrega, S Kapur Neuropsychopharmacology 32 (7), 1540-1549, 2007 | 58 | 2007 |
| Phosphodiesterase 10A PET radioligand development program: from pig to human C Plisson, D Weinzimmer, S Jakobsen, S Natesan, C Salinas, SF Lin, ... Journal of Nuclear Medicine 55 (4), 595-601, 2014 | 57 | 2014 |
Shitij KapurKing's College London在 kcl.ac.uk 的电子邮件经过验证
